BibTex RIS Cite

Adequacy of nucleer matrix protein 22 to determine recurrences in patients with bladder cancer

Year 2012, , 18 - 22, 01.01.2012

Emin Savaş Kılavuz Mehmet Tosun Ahmet Rıza Uras

https://doi.org/10.5505/abantmedj.2012.68077

Abstract

Aim: To investigate the ability of nuclear matrix protein 22 NMP22 to determine recurrence in patients underwent transurethral resection of bladder tumor TURM Material and methods: NMP22 measured in urine of 148 patients applied TUR-M. According to cystoscopy and pathology results, the sensitivity, specifity, positive and negative predictive value of NMP22 test was determined in patients suspected bladder cancer recurrancy. Furthermore, the effects of urine erythrocyte and leukocyte levels on NMP22 test were investigated. Results: We calculated the sensitivity %36.8, specifity %88, positive predictive value %32 and negative predictive value %90. There was statically significant relation between urine leukocyte amount and NMP22 r=0,237, p

Keywords

NMP22 bladder cancer TUR-M cystoscopy

References

  • American Cancer Society. Cancer facts and figures 2001. Atalanta: American Cancer Society, inc.
  • American Cancer Society. Cancer facts and figures 2000. Atalanta: American Cancer Society, inc.
  • Case RAM, Hosker ME, McDonald DB, et al. Tumors of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry. I. The role of aniline, benzidine, alphanaphthylamine and beta-naphthylamine. Br J Ind Med 1954; 11: 75-104.
  • Silverman DT, Hartge P, Morrison AS, Devesa SS. Epidemio- logy of bladder cancer. Hematol Oncol Clin North Am. 1992; 6:1–30.
  • Johansson SL, Cohen SM. Epidemiology and etiology of bladder cancer. Semin Surg Oncol 1997; 13: 291-298
  • Smith AH, Goycolea M, Haque R, et al. Marked increase in bladder and lung cancer mortality in a region of Northern Chi- le due to arsenic in drinking water. Am J Epidemiol 1998; 147: 660-669.
  • Tawfik HN. Carcinoma of the urinary baldder associated with schistosomiasis in Egypt. The possible causal relationship. In- ternational Symposium of the Princess Takamatsu Cancer Re- search Fund. 1987; 18: 197-199.
  • Berezney R, Coffey DS. Identification of a nuclear protein matrix. Biochemical and Biophysical Research Communicati- ons 1974; 60: 1410-1417.
  • Fey, E. G., Krochmalnik, G. and Penman, S. The non-chromatin substructures of the nucleus: the ribonucleoprotein (RNP)- containing and RNP-depleted matrices analyzed by sequen- tial fractionation and resinless section electron microscopy. J. Cell Biol. 1986; 102: 1654-1665.
  • Fey, E. G. and Penman, S. Nuclear matrix proteins reflect cell type of origin in cultured human cells. Proc. Nat. Acad. Sci. 1988; 85: 121-125.
  • Miller TE, Beausang LA, Winchell LF, Lidgard GP. Detection of nuclear matrix proteins in serum from cancer patients. Cancer Res 1992; 52:422 .
  • Mc Kenna M, Lei J-D, Whitters E, et al.Specific immunoassay for nuclear matrix apparatus protein22 (NMP22) , using the immulite analyser, poster A-64; American Association for Cli- nical Chemistry, 54th Annual Meeting and Clinical Lab Exposi- tion, Orlondo, FL, US; 2002.
  • Zippe C, Pandrangi L, Agarwal A: NMP22 is a sensitive, cost effective test in patients at risk for bladder cancer. J Urol. 1999; 161: 62-65.
  • Eissa S, Swellam M, Sadek M, Mourad MS, Ahmady OE, Khalifa A. Comparative evaluation of the nuclear matrix protein, fib- ronectin, urinary bladder cancer antigen and voided urine cy- tology in the detection of bladder tumors. J Urol 2002; 168: 465-469
  • Ponsky L, Sharma S, Pandrangi L, Kedia S, et al. Screening and monitoring for bladder cancer: reŞning use of NMP22. J Urol 2001; 162: 75–80
  • Boman H, Hedelin H, Holmang S. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. J Urol 2002; 167: 80-3.
  • Mahnert B, Tauber S, Kriegmair M, Nagel D, Holdenrieder S, Hofmann K, Reiter W, Schmeller N and Stieber P: Measure- ments of complement factor H-related protein (BTATRAK as- say) and nuclear matrix protein (NMP22 assay)-useful diag- nostic tools in the diagnosis of urinary bladder cancer? Clin Chem Lab Med 2003; 41: 104-10
  • Atsu N, Ekici S, Oge OO, Ergen A, Hascelik G and Ozen H: False- positive results of the NMP22 test due to hematuria. J Urol 2002; 167: 555-8

Nükleer matriks protein 22'nin mesane kanserli hastalarda rekürrensleri belirleyebilme yeterliliği

Year 2012, , 18 - 22, 01.01.2012

Emin Savaş Kılavuz Mehmet Tosun Ahmet Rıza Uras

https://doi.org/10.5505/abantmedj.2012.68077

Abstract

Amaç: Transüteral mesane tümörü rezeksiyonu TUR-M uygulanan hastalarda Nükleer Matriks Protein 22 NMP22 ’nin rekürrens belirleyebilme yeteneğinin araştırılması. Gereç ve Yöntem: TUR-M tedavisi uygulanmış 148 hastanın idrarında NMP22 ölçümü yapıldı. Sistoskopi sonuçlarına göre ve mesane kanseri rekürrensi şüphelenilip patolojiye gönderilen vakaların sonuçlarına göre NMP22 testinin duyarlılığı, özgüllüğü, pozitif ve negatif kestirim değeri belirlendi. Ayrıca idrardaki eritrosit ve lökosit düzeylerinin NMP22 testine etkisi araştırıldı. Bulgular: Duyarlılığı %36,8, özgüllüğü %88, negatif kestirim değeri %90, pozitif kestirim değeri %32 olarak hesapladık. İdrarda lökosit miktarı ile NMP22 değerleri arasında istatistikî bakımdan ilişki tespit ettik r=0,237, p

Keywords

NMP22 mesane kanseri TUR-M sistoskopi

References

  • American Cancer Society. Cancer facts and figures 2001. Atalanta: American Cancer Society, inc.
  • American Cancer Society. Cancer facts and figures 2000. Atalanta: American Cancer Society, inc.
  • Case RAM, Hosker ME, McDonald DB, et al. Tumors of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry. I. The role of aniline, benzidine, alphanaphthylamine and beta-naphthylamine. Br J Ind Med 1954; 11: 75-104.
  • Silverman DT, Hartge P, Morrison AS, Devesa SS. Epidemio- logy of bladder cancer. Hematol Oncol Clin North Am. 1992; 6:1–30.
  • Johansson SL, Cohen SM. Epidemiology and etiology of bladder cancer. Semin Surg Oncol 1997; 13: 291-298
  • Smith AH, Goycolea M, Haque R, et al. Marked increase in bladder and lung cancer mortality in a region of Northern Chi- le due to arsenic in drinking water. Am J Epidemiol 1998; 147: 660-669.
  • Tawfik HN. Carcinoma of the urinary baldder associated with schistosomiasis in Egypt. The possible causal relationship. In- ternational Symposium of the Princess Takamatsu Cancer Re- search Fund. 1987; 18: 197-199.
  • Berezney R, Coffey DS. Identification of a nuclear protein matrix. Biochemical and Biophysical Research Communicati- ons 1974; 60: 1410-1417.
  • Fey, E. G., Krochmalnik, G. and Penman, S. The non-chromatin substructures of the nucleus: the ribonucleoprotein (RNP)- containing and RNP-depleted matrices analyzed by sequen- tial fractionation and resinless section electron microscopy. J. Cell Biol. 1986; 102: 1654-1665.
  • Fey, E. G. and Penman, S. Nuclear matrix proteins reflect cell type of origin in cultured human cells. Proc. Nat. Acad. Sci. 1988; 85: 121-125.
  • Miller TE, Beausang LA, Winchell LF, Lidgard GP. Detection of nuclear matrix proteins in serum from cancer patients. Cancer Res 1992; 52:422 .
  • Mc Kenna M, Lei J-D, Whitters E, et al.Specific immunoassay for nuclear matrix apparatus protein22 (NMP22) , using the immulite analyser, poster A-64; American Association for Cli- nical Chemistry, 54th Annual Meeting and Clinical Lab Exposi- tion, Orlondo, FL, US; 2002.
  • Zippe C, Pandrangi L, Agarwal A: NMP22 is a sensitive, cost effective test in patients at risk for bladder cancer. J Urol. 1999; 161: 62-65.
  • Eissa S, Swellam M, Sadek M, Mourad MS, Ahmady OE, Khalifa A. Comparative evaluation of the nuclear matrix protein, fib- ronectin, urinary bladder cancer antigen and voided urine cy- tology in the detection of bladder tumors. J Urol 2002; 168: 465-469
  • Ponsky L, Sharma S, Pandrangi L, Kedia S, et al. Screening and monitoring for bladder cancer: reŞning use of NMP22. J Urol 2001; 162: 75–80
  • Boman H, Hedelin H, Holmang S. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. J Urol 2002; 167: 80-3.
  • Mahnert B, Tauber S, Kriegmair M, Nagel D, Holdenrieder S, Hofmann K, Reiter W, Schmeller N and Stieber P: Measure- ments of complement factor H-related protein (BTATRAK as- say) and nuclear matrix protein (NMP22 assay)-useful diag- nostic tools in the diagnosis of urinary bladder cancer? Clin Chem Lab Med 2003; 41: 104-10
  • Atsu N, Ekici S, Oge OO, Ergen A, Hascelik G and Ozen H: False- positive results of the NMP22 test due to hematuria. J Urol 2002; 167: 555-8
There are 18 citations in total.

Details

Primary Language Turkish
Journal Section Research Article
Authors

Emin Savaş Kılavuz This is me

Mehmet Tosun This is me

Ahmet Rıza Uras This is me

Publication Date January 1, 2012
Published in Issue Year 2012

Cite

APA Kılavuz, E. S., Tosun, M., & Uras, A. R. (2012). Nükleer matriks protein 22’nin mesane kanserli hastalarda rekürrensleri belirleyebilme yeterliliği. Abant Medical Journal, 1(1), 18-22. https://doi.org/10.5505/abantmedj.2012.68077
AMA Kılavuz ES, Tosun M, Uras AR. Nükleer matriks protein 22’nin mesane kanserli hastalarda rekürrensleri belirleyebilme yeterliliği. Abant Med J. January 2012;1(1):18-22. doi:10.5505/abantmedj.2012.68077
Chicago Kılavuz, Emin Savaş, Mehmet Tosun, and Ahmet Rıza Uras. “Nükleer Matriks Protein 22’nin Mesane Kanserli Hastalarda rekürrensleri Belirleyebilme yeterliliği”. Abant Medical Journal 1, no. 1 (January 2012): 18-22. https://doi.org/10.5505/abantmedj.2012.68077.
EndNote Kılavuz ES, Tosun M, Uras AR (January 1, 2012) Nükleer matriks protein 22’nin mesane kanserli hastalarda rekürrensleri belirleyebilme yeterliliği. Abant Medical Journal 1 1 18–22.
IEEE E. S. Kılavuz, M. Tosun, and A. R. Uras, “Nükleer matriks protein 22’nin mesane kanserli hastalarda rekürrensleri belirleyebilme yeterliliği”, Abant Med J, vol. 1, no. 1, pp. 18–22, 2012, doi: 10.5505/abantmedj.2012.68077.
ISNAD Kılavuz, Emin Savaş et al. “Nükleer Matriks Protein 22’nin Mesane Kanserli Hastalarda rekürrensleri Belirleyebilme yeterliliği”. Abant Medical Journal 1/1 (January 2012), 18-22. https://doi.org/10.5505/abantmedj.2012.68077.
JAMA Kılavuz ES, Tosun M, Uras AR. Nükleer matriks protein 22’nin mesane kanserli hastalarda rekürrensleri belirleyebilme yeterliliği. Abant Med J. 2012;1:18–22.
MLA Kılavuz, Emin Savaş et al. “Nükleer Matriks Protein 22’nin Mesane Kanserli Hastalarda rekürrensleri Belirleyebilme yeterliliği”. Abant Medical Journal, vol. 1, no. 1, 2012, pp. 18-22, doi:10.5505/abantmedj.2012.68077.
Vancouver Kılavuz ES, Tosun M, Uras AR. Nükleer matriks protein 22’nin mesane kanserli hastalarda rekürrensleri belirleyebilme yeterliliği. Abant Med J. 2012;1(1):18-22.